Since the discovery of X-rays, radiotherapy (RT) has been used widely in both primary and adjuvant treatment of cancer diseases, but some side effects of RT have occurred in addition to these curative effects. One of these side effects is ototoxicity. Hearing loss may be severe and uncomfortable enough to disrupt the life quality of some patients.
via the ATP pathway. 21, 22) Platelet anti-aggregant effects might be secondary to a direct inhibitory effect of piracetam on tromboxane A 2 or tromboxane A 2 synthetase in the chain of synthesis of platelet prostaglandins. The rheological effects of piracetam, especially those related to red cells, are probably related partly to cell membrane changes, such as lipid structure, prostaglandin synthesis, and degree of phosphorylation of spectrin, especially in erythrocytes but also in white cells and platelets, and partly to qualitative changes in some plasma protein fractions such as fibrinogen, macroglobulins and von Willebrand's factor. 20) The purpose of this study was to examine the protective effects of parenteral piracetam supplementation on cochlear damage occurring in guinea pigs exposed to total cranium irradiation.
MATERIALS AND METHODS

Animals, Drugs and Irradiation
All procedures including albino guinea pigs were carried out adhering to principles of the Use of Animals in Research. The guinea pigs were quarantined for at least 1 d before irradiation, housed in cages in a windowless laboratory room with automatic temperature (22Ϯ1°C) and lighting controls (12 h light/12 h dark), and fed standard laboratory chow and water ad libitum.
Male albino guinea pigs (450-600 g body weight) (nϭ 76) were randomly divided into three groups. Group 1 (Control group) (nϭ11) received neither PIR nor irradiation, but received saline solution (3.5 ml/kg) i.p. and received sham irradiation for five successive days. Group 2 (RT group) (nϭ32) was exposed to total cranium irradiation of 33 Gy in 5 fractions of 6.6 Gy/d for five successive days, with a calculated (a/bϭ3.5) biological effective dose of fractionated irradiation equal to 60 Gy conventional fractionation, plus receiving saline solution (3.5 ml/kg) i.p. for five successive days as a placebo. Group 3 (PIRϩRT group) (nϭ33) received total cranium irradiation, plus 350 mg/kg per day PIR (UCB Pharma, Istanbul, Turkey) for five successive days i.p. In our study, 350 mg/kg/d dose of piracetam (i.e. 3.5 ml/kg) was used 1 h before the total cranium irradiation.
Effects of Piracetam Supplementation on Cochlear Damage Occuring in Guinea Pigs Exposed to Irradiation
Prior to total cranium radiotherapy, the guinea pigs were anesthetized with 50 mg/kg ketamin HCl (Pfizer, Istanbul) and placed on a plexiglas tray in a prone position. The guinea pigs in the RT and PIRϩRT groups were irradiated using a cobalt-60 teletherapy unit (Picker, C-9, Maryland, NY, U.S.A.) from a source-to-surface distance of 80 cm, by 7.5ϫ7.5 cm anterior fields with 33 Gy to the total cranium in 5 fractions of 6.6 Gy/d for five successive days; the calculated (a/bϭ3.5) biological effective dose of fractionated irradiation was equal to 60 Gy conventional fractionation. The dose was calculated for the central axis at a depth of 1.5 cm. The dose rate was 0.65 Gy/min.
After the last dose of irradiation and/or drug, the guinea pigs were anesthetized by i.p. administration of 100 mg/kg of ketamine hydrochloride (Pfizer) and 3 mg/kg of diazepam (Deva, Istanbul), and were sacrificed with overdoses (100 mg/kg) of pentobarbital (Abbott, Istanbul) this was administered to all of the control group (nϭ11), 12 and 11 animals at the 4th hour from 2 and 3 groups, 10 and 12 animals at the 24th hour, and 10 and 10 animals at the 96th hour, respectively. Their right and left temporal bones were removed within 5 min of sacrifice and it was reached to the tympanic bulla after removal of the lateral wall of the mastoid like process of these temporal bones. Their left cochleas were enucleated for histopathologic examination, and their right temporal bones were used for another study.
Histopathological Evaluation The left tympanic bullas were fixed in 10% neutral buffered formaldehyde solution and kept in this solution at ϩ4°C for 24 h. For decalcification, specimens were stored in 10% ethylenediaminetetraacetic acid solution at 4°C for 20 d. All specimens were dehydrated, embedded in paraffin and serially cut into 5 mm slices. Sections were stained with haematoxylin and eosin for light microscopic examination by two independent pathologists. Changes in the organ of Corti (hydropic and vacuolar degeneration and loss of outer hair cells (OHC) and inner hair cell (IHC)); in spiral ganglion (SG) (cytoplasmic and nuclear condensation, nucleus and neuron loss); and in the stria vascularis (SV) (edema, vacuolization and loss of cells) were noted. While changes in SV were scored as absent (0), mild (1), moderate (2) or severe (3), the percentage of degenerated cells in SG and the number of degenerated cells in the organ of Corti were evaluated.
Statistical Analysis After necessary data had been collected, statistical analyses were made using the SPSS 11.0 packet programme (Statistical Package for Social Science; Windows version 11.0). The results were given as meansϮ standard deviation. Statistical significance of differences between the groups was tested with the One-way ANOVA test. pϽ0.05 was accepted as statistically significant.
RESULTS
There was no cochlear degeneration in the control group (Table 1 were compared with control group, cochlear damage in the guinea pigs at 4th, 24th and 96th hours was significant (pϽ0.05). We found that the total cranium irradiation (RT group) promoted degeneration in the SV (severe hydropic and vacuolar degeneration) (Fig. 2) , OHC and IHC (hydropic, vacuolar degeneration, and loss of cells) (Fig. 5) and SG (inconspicuous cytoplasmic and nuclear condensation, nucleus and neuron loss) (Fig. 8 ) of cochleas at 4th, 24th and 96th hours (pϽ0.05) ( Table 1) . PIR supplementation (PIRϩRT group) decreased damage in SV (mild hydropic and vacuolar degeneration) at 24th and 96th hours (Fig. 3) , OHC (hydropic degeneration) at 24th and 96th hours and IHC (hydropic degeneration) (Fig. 6 ) and SG (cytoplasmic and nuclear condensation, and loss of a few nucleus and neuron) at 4th, 24th and 96th hours (Fig. 9) , at 96th hour (pϽ0.05) the radiation-induced cochlear degeneration. But, none of these changes was not observed in SV and OHC at 4th and in the IHC at 4th and 24th hours (pϾ0.05) ( Tables 1,  2 ).
DISCUSSION
The goal of radiation treatment is to deliver completely measured doses of ionizing radiation to a defined tumor volume with the minimum acceptable injurious effects of ionizing radiation to surrounding healthy tissue by eliminating tumor cells, providing a high quality of life and prolongation of survival at reasonable cost to cancer patients. 24) Cochlear toxicity may occur, however, during radiation therapy of head and neck cancer. 1) In the literature we found that cochlear damage increased in proportion to RT dose. Kim and Shin 25) applied a single dose of 2, 6, 10, or 15 Gy to guinea pigs, and evaluated cochleas histopathologically. They found that OHC damage appeared with irradiation of more than 10 Gy, and IHC damage with irradiation of more than 15 Gy. They also found that the morphologic changes in SV were intercellular and perivascular fluid accumulation that have appeared to be a reversible process. Young et al. 26) carried out experimental studies in which they gave 2 Gy-dose ionized radiation to guinea pigs for 30 d, then evaluated the inner ear structure microscopically. They detected degeneration in support cells and in OHC of the Corti organ, in vessel endoteliocytes, reduction in the number of capillaries, atrophy and degeneration in SV. In the present study at the applied high RT dose of 60 Gy, we demonstrated that irradiation caused damage in all RT: radiotherapy groups; PIRϩRT: radiotherapy plus piracetam groups; h: hour; n: number; Deg: degenerated; SV: stria vascularis; SG: spiral ganglion the investigated parameters of SV, OHC, IHC and SG. Oxidative stress has an important place in ototoxicity pathophysiology. 27) Previous studies have suggested that cisplatin or aminoglycoside ototoxicity was related to an increase in lipid peroxidation and a decrease in endogenous antioxidant enzyme status. 28, 29) In cisplatin and aminoglycoside-induced ototoxicity, it has been reported that L-methionine, alpha lipoic acid, vitamin E, vitamin B, pantothenic acid, co-enzyme A, and piracetam were used as protective agents because of their antioxidant properties. [8] [9] [10] [11] [12] [13] [14] [15] Exposure of cells to ionizing radiation cause oxidative stress because it occurs through which a variety of reactive oxygen species, such as the superoxide radical (O 2 · Ϫ ), the hydrogen peroxide (H 2 O 2 ) and the hydroxyl radical (OH Ϫ ) that are associated with radiation-induced cytotoxicity 30) Although all respiring cells are equipped with protective enzymes such as SOD and CAT or GSH-Px, increased oxidative stress in cells stemming from ionizing radiation may overwhelm the protective systems, leading to cell injury. 31) Consequently, piracetam is a drug that has antioxidant, 22, 32, 33) platelet antiaggregant, rheological, [20] [21] [22] anti-inflammatory, 34) antiapoptotic, cytoprotective 35) and immunomodulatory effects. 36, 37) Minkova et al. 38) reported that 200 mg/kg piracetam combined with vitamin E 20 mg/kg and anthocyans 50 mg/kg has a radioprotective effect. They found that the combination significantly increased survival rate (50%) in mice, blood-forming organs underwent less radiation damage, and recovery processes in them were stimulated. In a recent study, we demonstrated that piracetam prevented ototoxicity by interfering with the neuroprotective mechanism in the guinea pigs in vivo. We also determined that piracetam improved the ototoxic effects of combined cisplatin-gentamicin upon auditory pathways from cochlea to middle brain. Thereby, we deduced that, because of the protective effects of piracetam, it was able to provide more effective treatment of otorhinolaryngologic, neurologic, infectious and oncologic diseases by reducing combined cisplatin-gentamicin ototoxicity. 15) In terms of the above expressed information, one can allege that piracetem might play a role by increasing oxygenation in the tumor cells with its rheological effects and decreasing apoptosis in surrounding healthy cells with its antiapoptotic effects in the prevention of radiation-induced oxidative damage. Animal studies showed that rats treated chronically with 100 to 1000 mg/kg orally for 6 months did not show any toxic effect; Nor were any teratogenic effects found. 39) Koskiniemi et al. 40) reported that a dose of 24 g/d for two weeks is highly beneficial, more effective than lower doses as an effective and safe medication in patients. Thus, a piracetam dose of 350 mg/kg/d in our study was similar to 24 g/d used in a 70 kg of human. The plasma elimination half-life was short in all the species studied, ranging from a mean of 1.8-2.0 and 4.5 h following administration in rats and man, respectively. 41, 42) Piracetam was used for 1 h to prevent barbiturate intoxication in rabbit. 13) We also used it 1 h before the total cranium irradiation. These are some of other reasons why we used piracetam as a potent radioprotector agent in the present study.
We found in this study that fractionated total cranium irradiation of 60 Gy (RT group) promoted damage in SV, SG, OHC and IHC of cochleas, and piracetam supplementation (PIRϩRT group) decreased the radiation-induced cochlear damage.
In conclusion, piracetam seems to have beneficial effects in the reduction of radiation-induced ototoxicity. These are pioneer results for studies that will be performed with PIR to protect from radiation toxicity. It would be worthwhile studying the effects of PIR supplements in radiation-treated cancer patients, in the hope of reducing radiation-induced toxicity.
